Mehdi Hamadani

Ontology type: schema:Person     

Person Info





Publications in SciGraph latest 50 shown

  • 2019-12 Allogeneic hematopoietic cell transplantation provides effective salvage despite refractory disease or failed prior autologous transplant in angioimmunoblastic T-cell lymphoma: a CIBMTR analysis in JOURNAL OF HEMATOLOGY & ONCOLOGY
  • 2018-12 Repurposing existing medications as cancer therapy: design and feasibility of a randomized pilot investigating propranolol administration in patients receiving hematopoietic cell transplantation in BMC CANCER
  • 2018-11-16 Antithymocyte globulin for graft-versus-host disease prophylaxis: an updated systematic review and meta-analysis in BONE MARROW TRANSPLANTATION
  • 2018-09 Use of propylene glycol-free melphalan conditioning in light-chain amyloidosis patients undergoing autologous hematopoietic cell transplantation is well tolerated and effective in BONE MARROW TRANSPLANTATION
  • 2018-05 Neurocognitive dysfunction in hematopoietic cell transplant recipients: expert review from the late effects and Quality of Life Working Committee of the CIBMTR and complications and Quality of Life Working Party of the EBMT in BONE MARROW TRANSPLANTATION
  • 2018 Indications for Allogeneic Hematopoietic Stem Cell Transplantation in Adults in ESTABLISHING A HEMATOPOIETIC STEM CELL TRANSPLANTATION UNIT
  • 2018 Haploidentical Hematopoietic Cell Transplantation in Lymphomas in HAPLOIDENTICAL TRANSPLANTATION
  • 2017-12 Rituximab-containing reduced-intensity conditioning improves progression-free survival following allogeneic transplantation in B cell non-Hodgkin lymphoma in JOURNAL OF HEMATOLOGY & ONCOLOGY
  • 2017-12 Observational study of lenalidomide in patients with mantle cell lymphoma who relapsed/progressed after or were refractory/intolerant to ibrutinib (MCL-004) in JOURNAL OF HEMATOLOGY & ONCOLOGY
  • 2017-11 Is myeloablative dose intensity necessary in allogeneic hematopoietic cell transplantation for lymphomas? in BONE MARROW TRANSPLANTATION
  • 2017-09 Trends in pre- and post-transplant therapies with first autologous hematopoietic cell transplantation among patients with multiple myeloma in the United States, 2004–2014 in LEUKEMIA
  • 2017-07 Treatment of severe mucositis pain with oral ketamine mouthwash in SUPPORTIVE CARE IN CANCER
  • 2017-02 Long-term outcomes after thiotepa-based high-dose therapy (HDT) and autologous hematopoietic cell transplantation (auto-HCT) in non-Hodgkin lymphoma (NHL) in BONE MARROW TRANSPLANTATION
  • 2017-02 Metabolic syndrome and cardiovascular disease following hematopoietic cell transplantation: screening and preventive practice recommendations from CIBMTR and EBMT in BONE MARROW TRANSPLANTATION
  • 2017-01 Salvage haploidentical hematopoietic cell transplantation for graft rejection following a prior haploidentical allograft in BONE MARROW TRANSPLANTATION
  • 2016-12 Impact of haploidentical hematopoietic cell transplantation conditioning intensity on the incidence and severity of post-transplantation viral infections in BONE MARROW TRANSPLANTATION
  • 2016-11 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one in JOURNAL FOR IMMUNOTHERAPY OF CANCER
  • 2016-10 Impact of intravenous magnesium infusion rate during ambulatory replacements on serum magnesium concentrations after allogeneic stem cell transplant in SUPPORTIVE CARE IN CANCER
  • 2016-02 Presentation and management of post-allogeneic transplantation EBV-positive mucocutaneous ulcer in BONE MARROW TRANSPLANTATION
  • 2016-01 Long-term survival outcomes of reduced-intensity allogeneic or autologous transplantation in relapsed grade 3 follicular lymphoma in BONE MARROW TRANSPLANTATION
  • 2015-12 Contribution of chemotherapy mobilization to disease control in multiple myeloma treated with autologous hematopoietic cell transplantation in BONE MARROW TRANSPLANTATION
  • 2015-11 Post-autologous transplant maintenance therapies in lymphoid malignancies: are we there yet? in BONE MARROW TRANSPLANTATION
  • 2015-11 A prognostic model predicting autologous transplantation outcomes in children, adolescents and young adults with Hodgkin lymphoma in BONE MARROW TRANSPLANTATION
  • 2015-08 Secondary solid cancer screening following hematopoietic cell transplantation in BONE MARROW TRANSPLANTATION
  • 2015-08 Allogeneic hematopoietic cell transplant for AML: no impact of pre-transplant extramedullary disease on outcome in BONE MARROW TRANSPLANTATION
  • 2015-04 Superior efficacy but higher cost of plerixafor and abbreviated-course G-CSF for mobilizing hematopoietic progenitor cells (HPC) in AL amyloidosis in BONE MARROW TRANSPLANTATION
  • 2015-03 Chronic GVHD and concurrent new-onset nephrotic syndrome in allogeneic transplant recipients. Incidence, pattern and therapeutic outcomes in BONE MARROW TRANSPLANTATION
  • 2014-05 Managing Hodgkin lymphoma relapsing after autologous hematopoietic cell transplantation: a not-so-good cancer after all! in BONE MARROW TRANSPLANTATION
  • 2014-04 Impact of the duration of antiviral prophylaxis on rates of varicella-zoster virus reactivation disease in autologous hematopoietic cell transplantation recipients in ANNALS OF HEMATOLOGY
  • 2013-12 Comparative efficacy of tandem autologous versus autologous followed by allogeneic hematopoietic cell transplantation in patients with newly diagnosed multiple myeloma: a systematic review and meta-analysis of randomized controlled trials in JOURNAL OF HEMATOLOGY & ONCOLOGY
  • 2013-11 Is hematopoietic cell transplantation still a valid option for mantle cell lymphoma in first remission in the chemoimmunotherapy-era? in BONE MARROW TRANSPLANTATION
  • 2013-11 Safety and disease response to MEDI-551, an anti-CD19 antibody, in chronic lymphocytic leukemia patients previously treated with rituximab in JOURNAL FOR IMMUNOTHERAPY OF CANCER
  • 2013-10 Comparable efficacy and lower cost of PBSC mobilization with intermediate-dose cyclophosphamide and G-CSF compared with plerixafor and G-CSF in patients with multiple myeloma treated with novel therapies in BONE MARROW TRANSPLANTATION
  • 2013-08 Reappraising the role of autologous transplantation for indolent B-cell lymphomas in the chemoimmunotherapy era: is it still relevant? in BONE MARROW TRANSPLANTATION
  • 2012-01 Impact of response to thalidomide-, lenalidomide- or bortezomib- containing induction therapy on the outcomes of multiple myeloma patients undergoing autologous transplantation in BONE MARROW TRANSPLANTATION
  • 2010-08 How we approach patient evaluation for hematopoietic stem cell transplantation in BONE MARROW TRANSPLANTATION
  • 2007-08 Paraneoplastic Sweet’s syndrome and the pathergy phenomenon in ANNALS OF HEMATOLOGY
  • 2007-02 Central nervous system post-transplant lymphoproliferative disorder despite negative serum and spinal fluid Epstein–Barr virus DNA PCR in BONE MARROW TRANSPLANTATION
  • JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

        "@context": "", 
        "affiliation": [
            "affiliation": {
              "id": "", 
              "type": "Organization"
            "isCurrent": true, 
            "type": "OrganizationRole"
            "id": "", 
            "type": "Organization"
            "id": "", 
            "type": "Organization"
            "id": "", 
            "type": "Organization"
            "id": "", 
            "type": "Organization"
            "id": "", 
            "type": "Organization"
            "id": "", 
            "type": "Organization"
            "id": "", 
            "type": "Organization"
            "id": "", 
            "type": "Organization"
            "id": "", 
            "type": "Organization"
        "familyName": "Hamadani", 
        "givenName": "Mehdi", 
        "id": "sg:person.01333152475.54", 
        "identifier": {
          "name": "orcid_id", 
          "type": "PropertyValue", 
          "value": [
        "sameAs": [
        "sdDataset": "persons", 
        "sdDatePublished": "2019-03-07T14:51", 
        "sdLicense": "", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        "sdSource": "s3://com-uberresearch-data-dimensions-researchers-20181010/20181011/dim_researchers/base/researchers_583.json", 
        "type": "Person"

    Download the RDF metadata as:  json-ld nt turtle xml License info


    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' ''

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' ''

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' ''

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' ''


    This table displays all metadata directly associated to this object as RDF triples.

    39 TRIPLES      11 PREDICATES      22 URIs      8 LITERALS      3 BLANK NODES

    Subject Predicate Object
    1 sg:person.01333152475.54 schema:affiliation Neb58545581a6497b9f1f8bd25ac4e1de
    11 schema:familyName Hamadani
    12 schema:givenName Mehdi
    13 schema:identifier Nee2fb372d1634228af08dbb30f92179f
    14 schema:sameAs
    16 schema:sdDatePublished 2019-03-07T14:51
    17 schema:sdLicense
    18 schema:sdPublisher N9b4433a404284c8a933c49cbc63e732b
    19 sgo:license sg:explorer/license/
    20 sgo:sdDataset persons
    21 rdf:type schema:Person
    22 N9b4433a404284c8a933c49cbc63e732b schema:name Springer Nature - SN SciGraph project
    23 rdf:type schema:Organization
    24 Neb58545581a6497b9f1f8bd25ac4e1de schema:affiliation
    25 sgo:isCurrent true
    26 rdf:type schema:OrganizationRole
    27 Nee2fb372d1634228af08dbb30f92179f schema:name orcid_id
    28 schema:value 0000-0001-5372-510X
    29 rdf:type schema:PropertyValue
    30 schema:Organization
    31 schema:Organization
    32 schema:Organization
    33 schema:Organization
    34 schema:Organization
    35 schema:Organization
    36 schema:Organization
    37 schema:Organization
    38 schema:Organization
    39 schema:Organization

    Preview window. Press ESC to close (or click here)